Member
Consegna Pharma Inc.
Consegna Pharma Inc. is a specialty pharmaceutical company dedicated to creating best-in-class long-acting medications. With a mission to improve health outcomes, the company focuses on developing innovative drug delivery solutions, such as long-acting formulations for critical medications. Their lead product aims to address the opioid overdose crisis by providing extended protection against renarcotization, reflecting their commitment to 'Computing Better Health™'.
Industries
biotechnology
pharmaceutical
Nr. of Employees
small (1-50)
Consegna Pharma Inc.
2403 Sidney St., Suite 285, Pittsburgh PA 15203
Products
Long-acting naloxone formulation (12–24 hour release)
A sustained-release naloxone formulation designed to provide 12–24 hours of drug exposure to reduce the need for repeated dosing and help prevent renarcotization after opioid overdose.
Long-acting naloxone formulation (12–24 hour release)
A sustained-release naloxone formulation designed to provide 12–24 hours of drug exposure to reduce the need for repeated dosing and help prevent renarcotization after opioid overdose.
Expertise Areas
- Long-acting drug delivery
- Formulation development
- Opioid overdose therapeutics
- Sustained-release product design
Key Technologies
- Sustained-release / extended-release formulations
- Long-acting drug delivery systems
- Controlled-release formulation techniques
Key People
Investors
National Institute on Drug Abuse (NIDA)
Announced on 2019-12-18.
National Institute on Drug Abuse (NIDA)
Announced on 2019-12-18.